| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations
|
Boeve, Bradley F
|
|
|
21 |
3 |
p. 258-272
|
article
|
| 2 |
Advancing the diagnosis of repeat expansion disorders
|
Lockhart, Paul J
|
|
|
21 |
3 |
p. 205-207
|
article
|
| 3 |
Arianna Tucci
|
|
|
|
21 |
3 |
p. 222
|
article
|
| 4 |
Brain health in the Philippines
|
Osorio, Lorena Margarita B
|
|
|
21 |
3 |
p. 216-217
|
article
|
| 5 |
Brains are neither pink nor blue but fifty shades of grey matter
|
Ranscombe, Peter
|
|
|
21 |
3 |
p. 223
|
article
|
| 6 |
Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions
|
Al-Hassany, Linda
|
|
|
21 |
3 |
p. 284-294
|
article
|
| 7 |
CGRP-targeted drugs for migraine: still many uncertainties
|
Diener, Hans Christoph
|
|
|
21 |
3 |
p. 209-210
|
article
|
| 8 |
Correction to Lancet Neurol 2022; 21: 125–39
|
|
|
|
21 |
3 |
p. e3
|
article
|
| 9 |
Correction to Lancet Neurol 2022; 21: 42–52
|
|
|
|
21 |
3 |
p. e3
|
article
|
| 10 |
Correction to Lancet Neurol 2022; 21: 189–202
|
|
|
|
21 |
3 |
p. e3
|
article
|
| 11 |
Correction to Lancet Neurol 2019; 18: 329–31
|
|
|
|
21 |
3 |
p. e3
|
article
|
| 12 |
Expression of concern—Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study
|
The Lancet Neurology Editors,
|
|
|
21 |
3 |
p. 210
|
article
|
| 13 |
Karin Klijn: driven by a love of neurology and equality
|
Venkatesan, Priya
|
|
|
21 |
3 |
p. 221
|
article
|
| 14 |
Making a difference for motor neuron diseases
|
Samarasekera, Udani
|
|
|
21 |
3 |
p. 219-220
|
article
|
| 15 |
Management of atherosclerotic extracranial carotid artery stenosis
|
Bonati, Leo H
|
|
|
21 |
3 |
p. 273-283
|
article
|
| 16 |
MOG antibody-associated disease after vaccination with ChAdOx1 nCoV-19
|
Francis, Anna
|
|
|
21 |
3 |
p. 217-218
|
article
|
| 17 |
Multiple sclerosis: two decades of progress
|
Cree, Bruce A C
|
|
|
21 |
3 |
p. 211-214
|
article
|
| 18 |
Rare diseases: maintaining momentum
|
The Lancet Neurology,
|
|
|
21 |
3 |
p. 203
|
article
|
| 19 |
Riluzole and spinocerebellar ataxia type 2: the ATRIL trial
|
Velázquez-Pérez, Luis
|
|
|
21 |
3 |
p. 204-205
|
article
|
| 20 |
Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial
|
Coarelli, Giulia
|
|
|
21 |
3 |
p. 225-233
|
article
|
| 21 |
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
|
Benkert, Pascal
|
|
|
21 |
3 |
p. 246-257
|
article
|
| 22 |
The crucial history of Down syndrome
|
Zaman, Shahid
|
|
|
21 |
3 |
p. 222
|
article
|
| 23 |
The pain of a migraine
|
Morgan, Jules
|
|
|
21 |
3 |
p. 224
|
article
|
| 24 |
The prognostic value of neurofilament light chain in serum
|
Sellebjerg, Finn
|
|
|
21 |
3 |
p. 207-208
|
article
|
| 25 |
The reality of multiple sclerosis assessment in middle-income countries
|
Abramov, Dimitri Marques
|
|
|
21 |
3 |
p. 215
|
article
|
| 26 |
The reality of multiple sclerosis assessment in middle-income countries – Authors' reply
|
Rovira, Àlex
|
|
|
21 |
3 |
p. 215-216
|
article
|
| 27 |
Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study
|
Ibañez, Kristina
|
|
|
21 |
3 |
p. 234-245
|
article
|
Journal description